Enlivex Therapeutics Ltd. (1BT.F)

1.4400 -0.0400 (-2.70%) At close: 08:02AM CEST

Enlivex Therapeutics Ltd.

14 Einstein Street
Ness Ziona 7403618
Israel
972 8 662 3301
https://www.enlivex.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Shai Novik M.B.A.	Executive Chairman	490.39k	N/A	1966
Dr. Oren Hershkovitz Ph.D.	Chief Executive Officer	254.11k	N/A	1977
Mr. Veronique Amor-Baroukh	Senior Director of Operations	N/A	N/A	N/A
Ms. Sigal Arad	Director of HR	N/A	N/A	N/A

Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Corporate governance

Enlivex Therapeutics Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.